Ned Davis Research Downgrades Hologic to Sell (HOLX)
Hologic (NASDAQ:HOLX) was downgraded by Ned Davis Research from a “neutral” rating to a “sell” rating in a research note issued on Monday, StockRatingsNetwork.com reports.
In other Hologic news, CFO Glenn Muir unloaded 28,000 shares of Hologic stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $20.45, for a total transaction of $572,600.00. Following the completion of the transaction, the chief financial officer now directly owns 825,891 shares of the company’s stock, valued at approximately $16,889,471. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Shares of Hologic (NASDAQ:HOLX) traded down 1.00% on Monday, hitting $20.70. 922,850 shares of the company’s stock traded hands. Hologic has a one year low of $18.46 and a one year high of $23.96. The stock’s 50-day moving average is $21.46 and its 200-day moving average is $21.20. The company’s market cap is $5.598 billion.
Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, August 5th. The company reported $0.38 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.37 by $0.01. The company had revenue of $626.10 million for the quarter, compared to the consensus estimate of $627.05 million. During the same quarter last year, the company posted $0.35 earnings per share. Hologic’s revenue was up 33.2% compared to the same quarter last year. Analysts expect that Hologic will post $1.48 EPS for the current fiscal year.
A number of other firms have also recently commented on HOLX. Analysts at ISI Group upgraded shares of Hologic (NASDAQ:HOLX) from a “buy” rating to a “strong-buy” rating in a research note to investors on Tuesday, September 24th. They now have a $25.50 price target on the stock, up previously from $25.00. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Hologic (NASDAQ:HOLX) in a research note to investors on Wednesday, September 18th. They now have a $22.00 price target on the stock. Finally, analysts at TheStreet downgraded shares of Hologic (NASDAQ:HOLX) to a “hold” rating in a research note to investors on Tuesday, September 17th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Hologic currently has an average rating of “Buy” and a consensus price target of $23.88.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.